Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis

BACKGROUND: We have previously conducted the Sirolimus and Autophagy Inhibition in LAM (SAIL) trial, a phase 1 dose-escalation study of the combination of sirolimus and hydroxychloroquine in patients with lymphangioleiomyomatosis (LAM). The goal of the present study was to analyze sera from the SAIL...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Chest
Autors principals: Lamattina, Anthony M., Taveira-Dasilva, Angelo, Goldberg, Hilary J., Bagwe, Shefali, Cui, Ye, Rosas, Ivan O., Moss, Joel, Henske, Elizabeth P., El-Chemaly, Souheil
Format: Artigo
Idioma:Inglês
Publicat: American College of Chest Physicians 2018
Matèries:
Diffuse Lung Disease
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6224706/
https://ncbi.nlm.nih.gov/pubmed/30144422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chest.2018.08.1029
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars